C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
4.000
-0.030 (-0.74%)
At close: Aug 21, 2026, 4:00 PM EDT
4.051
+0.051 (1.28%)
After-hours: Aug 21, 2026, 7:55 PM EDT
C4 Therapeutics Stock Forecast
Stock Price Forecast
According to 7 analysts polled by S&P Global, C4 Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $13.33. The average 1-year stock price forecast is 233.25% higher than the current stock price, while the lowest is $7.00 (+75.00%) and the highest is $30 (+650.00%).
Price Target: $13.33 (+233.25%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for C4 Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 6 | 6 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Reiterates $10 | Buy | Reiterates | $10 | +150.00% | Aug 12, 2026 |
| Barclays | Barclays | Buy Maintains $7 | Buy | Maintains | $7 | +75.00% | Aug 12, 2026 |
| TD Cowen | TD Cowen | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Aug 12, 2026 |
| Jefferies | Jefferies | Buy Maintains $14 | Buy | Maintains | $14 | +250.00% | Apr 30, 2026 |
| Guggenheim | Guggenheim | Buy Reiterates $7 | Buy | Reiterates | $7 | +75.00% | Feb 27, 2026 |
Financial Forecast
Revenue This Year
21.43M
from 35.95M
Decreased by -40.40%
Revenue Next Year
20.54M
from 21.43M
Decreased by -4.13%
EPS This Year
-0.89
from -1.14
EPS Next Year
-1.00
from -0.89
EPS and Forward PE are based on non-GAAP adjusted numbers.